SB3000 is a ground-breaking life science company, which has developed a patented green technology platform for use in the continuous manufacturing of pharmaceuticals.
SB3000 is initially focused on replacing traditional batch manufacturing in the production of peptide therapeutics, which are particularly expensive and environmentally damaging to produce.
SB3000 is partnering with several international companies, who are leaders in the manufacture and installation of manufacturing plant, to incorporate the μlot technology to enable continuous manufacturing.
Advantages of μLOT technology over the legacy multi billion a year batch processing of pharmaceuticals
- Green – Reduction in the use of toxic chemicals (such as solvents) by up to 100 times
- Better quality – Improving product quality through continuous monitoring and control of the production line through Production Automated Technology (PAT) and OneGo™, which was developed by SB3000, as a way to perform multifactorial process optimization.
- Reduction in capex – Dramatically reducing existing capital costs and making it possible to avoid building new multi-billion dollar manufacturing plants
- Easily transportable – The μLOT enabled modules are easily transportable anywhere and at any time due to their modular nature and smaller footprint, enabling multiple on-shore manufacturing operations that can be commissioned more rapidly.
- Eliminates the need for a large quality control department as quality control is built into the μLOT technology through PAC and OneGo™.
- No need to scale up The process development is done once noand for all before the initial batch based on OneGoTM.
- Flexible -The μLOT technology enables adjustments to be made to the existing CM production line to accommodate different types of pharmaceuticals. No need to build a new plant.
- Downsizes the upstream and downstream processes Continuous small quantities rather than tens of kilos at intervals allowing for significantly smaller and more flexible facilities.
- Pressure from regulatory authorities – particularly FDA - to move to CM as well as international agreements such as Paris 2025.
- SB3000 has recently signed a Research Agreement with a top-ten global pharma company.
- SB3000ApS establishes headquarters in Copenhagen
- SB3000 has a letter of intent from a top EU based specialty pharma company
- SB3000 successfully demonstrates a proof of concept in first ever - continuous synthesis of a therapeutic peptide
- Zsolt Lavotha Appointed Acting CEO of SB3000
Increasing interest in peptides
Renewed interest in peptides has led to a number of highly successful ‘blockbuster’ peptide drugs such as Copaxone (glatiramer acetate) from Teva for multiple sclerosis, Victoza (liraglutide) from Novo Nordisc for diabetes and Lupron (leuprolide Acetate) from AbbVie in oncology.
As of 2018, more than 100 approved peptide therapeutics are used across many therapeutic areas including cancer, diabetes and autoimmune diseases. Additionally, a robust clinical pipeline includes close to 100 candidates in late stage clinical development, and more than 200 in early phase clinical development.
Sales of peptide-based medicines are projected to rise to over $50 billion by 2025.